<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1521">
  <stage>Registered</stage>
  <submitdate>4/04/2007</submitdate>
  <approvaldate>4/04/2007</approvaldate>
  <nctid>NCT00457119</nctid>
  <trial_identification>
    <studytitle>Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients</studytitle>
    <scientifictitle>A Two-step Phase 1 Study Investigating the Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients Not Treated Previously With Systemic Therapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2006-002760-26</secondaryid>
    <secondaryid>CRAD001C2114</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non Small Cell Lung Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Mesothelioma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - RAD001

Experimental: Step 1 Arm 1 - 5mg/day RAD001 + Carboplatin + Paclitaxel

Experimental: Step 1, Arm 2 - 30mg/week RAD001 + Carboplatin + Paclitaxel

Experimental: Step 2, Arm 1 - 5mg/day RAD001 + Carboplatin + Paclitaxel + Bevacizumab

Experimental: Step 2, Arm 2 - 30mg/week RAD001 + Carboplatin + Paclitaxel + Bevacizumab


Treatment: drugs: RAD001
5mg oral tablets of RAD001 - for the 5mg/daily arm, 10mg oral tablets x 3 of RAD001 - for the 30mg/weekly arm

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Establish the feasible doses/regimens of RAD001 in combination with chemotherapy. Primary endpoint is the End-of-cycle DLT rate</outcome>
      <timepoint>Ever 3 months or once a critical DLT occurs</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Relative dose intensity (RDI) of Carboplatin + Paclitaxel (step 1)</outcome>
      <timepoint>End of step 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Relative dose intensity (RDI) of Carboplatin + Paclitaxel + bevacizumab (step 2)</outcome>
      <timepoint>End of Step 2</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameters derived from PK profiles of treatment drugs alone and in combination</outcome>
      <timepoint>End of Step 1 and Step 2</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Best overall response - measured by CT/MRI scan every 6-8 week</outcome>
      <timepoint>Every 6-8 week</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Age over 18 years

          -  Advanced Non Small Cell Lung Cancer (Stage IIIB/IV)

          -  Ability to perform normal daily functions</inclusivecriteria>
    <inclusiveminage>23</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>76</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Chronic steroid treatment

          -  Prior treatment with chemotherapy for advanced lung cancer

          -  Prior treatment with mTOR inhibitors

          -  Active bleeding conditions, skin conditions, gastrointestinal disorders, mouth ulcers,
             eye conditions, chronic liver or kidney disorders, uncontrolled diabetes, infections
             or other severe medical conditions

          -  Known sensitivity to platinum compounds, taxanes or bevacizumab

          -  Other cancers within the past 5 years

          -  Pregnant or breastfeeding women Other protocol-defined inclusion/exclusion criteria
             may apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>69</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC</recruitmentstate>
    <hospital>Novartis Investigative Site - Adelaide</hospital>
    <hospital>Novartis Investigative Site - Heidelberg</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This 2 step study aims to establish a tolerable dose level and regimen of RAD001 in patients
      with advanced NCLC not previously treated with systemic therapy. In step 1 of this study, RAD
      001 is given in combination with carboplatin and paclitaxel and in Step 2 RAD001 is given in
      combination with carboplatin, paclitaxel and bevacizumab</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00457119</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>